Advertisement

PharmacoEconomics

, Volume 19, Issue 5, pp 449–468 | Cite as

Hip Fracture Prevention

Cost-Effective Strategies
Review Article

Abstract

The available literature on cost benefit, cost effectiveness and cost utility of different drug and non-drug regimens in preventing hip fractures was reviewed.

The cost of a hip fracture and of the different treatment regimens varied considerably from one country to another. In primary prevention, potential savings only exceeded costs in women over the age of 70 years treated with hormonal replacement therapy (HRT). In the case of HRT, treating those with low bone mineral density levels (secondary prevention) seems to be more cost effective than general treatment (primary prevention).

There are few studies that have compared several different preventive regimens. Cost effectiveness is directly related to the cost of the regimen used because there is no significant difference in their effectiveness. That is, a high cost regimen such as bisphosphonates would be less cost effective than a low cost regimen such as HRT, judged from existing literature.

High risk groups can be identified (nursing home residents) and treated with low cost interventions (calcium plus vitamin D or hip protectors). Considerable differences in the estimates used for the efficacy of different regimens in studies exist.

Further studies comparing several hip fracture preventive regimens are required in order to establish the most cost-effective strategy.

Keywords

Bone Mineral Density Vertebral Fracture Alendronate Risedronate Nursing Home Resident 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Research librarian, Miss Edith Clausen is acknowledged for skilful technical assistance.

References

  1. 1.
    Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 24–35PubMedCrossRefGoogle Scholar
  2. 2.
    Phillips S, Fox N, Jacobs J, et al. The direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone 1988; 9: 271–9PubMedCrossRefGoogle Scholar
  3. 3.
    Chriscilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone 1994; 15: 377–86CrossRefGoogle Scholar
  4. 4.
    Cummings SR, Rubin SM, Black D. The future of hip fractures in the United States: numbers, costs, and potential effects of postmenopausal estrogen. Clin Orthop 1990; (252): 163–6Google Scholar
  5. 5.
    Reginster JY, Gillet P, Ben Sedrine W, et al. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 1999; 15 (5): 507–14PubMedCrossRefGoogle Scholar
  6. 6.
    Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 1998; 8: 611–7PubMedCrossRefGoogle Scholar
  7. 7.
    Hollingworth W, Todd CJ, Parker MJ. The cost of treating hip fractures in the twenty-first century. J Public Health Med 1995; 17: 269–76PubMedGoogle Scholar
  8. 8.
    Cox MA, Bowie R, Horne G. Hip fractures: an increasing health care cost. J Orthop Trauma 1993; 7: 52–7PubMedCrossRefGoogle Scholar
  9. 9.
    Barrett-Connor E. The economic and human costs of osteoporotic fracture. Am J Med 1995; 98: 3S–8SPubMedCrossRefGoogle Scholar
  10. 10.
    Jensen JS, Tondevold E, Sorensen PH. Costs of treatment of hip fractures: a calculation of the consumption of the resources of hospitals and rehabilitation institutions. Acta Orthop Scand 1980; 51: 289–96PubMedCrossRefGoogle Scholar
  11. 11.
    Norris RJ. Medical costs of osteoporosis. Bone 1992; 13 Suppl. 2: S11–6PubMedCrossRefGoogle Scholar
  12. 12.
    Owen RA, Melton LJ, Gallagher JC, et al. The national cost of acute care of hip fractures associated with osteoporosis. Clin Orthop 1980; 172–6Google Scholar
  13. 13.
    Cooper C, Campion G, Melton III LJ. Hip fractures in the elderly: a world-wide projection. Osteoporosis Int 1992; 2: 285–9CrossRefGoogle Scholar
  14. 14.
    Baudoin C, Fardellone P, Thelot B, et al. Hip fractures in France: the magnitude and perspective of the problem. Osteoporos Int 1996; 6 Suppl. 3: 1–10PubMedCrossRefGoogle Scholar
  15. 15.
    Rodriguez JG, Sattin RW, Waxweiler RJ. Incidence of hip fractures, United States, 1970–83. Am J Prev Med 1989; 5: 175–81PubMedGoogle Scholar
  16. 16.
    Bacon WE, Maggi S, Looker A, et al. International comparison of hip fracture rates in 1988–89. Osteoporosis Int 1996; 6: 69–75CrossRefGoogle Scholar
  17. 17.
    Melton III LJ, Ilstrup DM, Riggs BL, et al. Fifty-year trend in hip fracture incidence. Clin Orthop 1982; 162: 144–9PubMedGoogle Scholar
  18. 18.
    Kelly TJ. Bone mineral density reference database for American men and women. J Bone Miner Res 1990; 5 Suppl. 2: S249Google Scholar
  19. 19.
    Alexeeva L, Burkhardt P, Christiansen C, et al. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. 1st ed. Geneva: World Health Organization (WHO), 1994. (WHO Technical Report, No. 843)Google Scholar
  20. 20.
    Naessen T, Lindmark B, Larsen HC. Better postural balance in elderly women receiving estrogens. Am J Obstet Gynecol 1997; 177: 412–6PubMedCrossRefGoogle Scholar
  21. 21.
    Hayes WC, Myers ER. Biomechanics of fractures. In: Riggs BL, Melton III LJ, editors. Osteoporosis: etiology, diagnosis and management. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1995: 93–114Google Scholar
  22. 22.
    Blake GM, Wahner HW, Fogelman I. The evaluation of osteoporosis: dual energy X-ray absorptiometry and ultrasound in clinical practice. 2nd ed. London: Martin Dunitz, 1999Google Scholar
  23. 23.
    Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254–9PubMedCrossRefGoogle Scholar
  24. 24.
    Gärdsell P, Johnell O, Nilsson BE, et al. The predictive value of fracture, disease, and falling tendency for fragility fractures in women. Calcif Tissue Int 1989; 45: 327–30PubMedCrossRefGoogle Scholar
  25. 25.
    Ensrud KE, Nevitt MC, Yunis C, et al. Postural hypotension and postural dizziness in elderly women: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. Arch Intern Med 1992; 152: 1058–64PubMedCrossRefGoogle Scholar
  26. 26.
    Cummings SR, Black D. Should perimenopausal women be screened for osteoporosis?. Ann Intern Med 1986; 104: 817–23PubMedGoogle Scholar
  27. 27.
    Tosteson ANA, Rosenthal DI, Melton III LJ, et al. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990; 113: 594–603PubMedGoogle Scholar
  28. 28.
    Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37PubMedGoogle Scholar
  29. 29.
    Mosekilde L, Beck-Nielsen H, Sørensen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women — results of the Danish Osteoporosis Prevention Study. Maturitas 2000; 36: 181–93PubMedCrossRefGoogle Scholar
  30. 30.
    Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 319–24PubMedGoogle Scholar
  31. 31.
    Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1–9PubMedGoogle Scholar
  32. 32.
    Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081–2PubMedCrossRefGoogle Scholar
  33. 33.
    Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D, and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637–42PubMedCrossRefGoogle Scholar
  34. 34.
    Tilyard MW, Spears GF, Thomson J, et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326: 357–62PubMedCrossRefGoogle Scholar
  35. 35.
    Orimo H, Shiraki M, Hayashi Y, et al. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994; 54: 370–6PubMedCrossRefGoogle Scholar
  36. 36.
    van Staa TP, Abenhaim L, Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheum 1998; 37: 87–94CrossRefGoogle Scholar
  37. 37.
    Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73–9PubMedCrossRefGoogle Scholar
  38. 38.
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077–82PubMedCrossRefGoogle Scholar
  39. 39.
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–41PubMedCrossRefGoogle Scholar
  40. 40.
    McClung M, Eastell R, Bensen W, et al. Risedronate reduces hip fracture risk in elderly women with osteoporosis [abstract]. Osteoporosis Int 2000; 11 Suppl. 2: S207Google Scholar
  41. 41.
    Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344–52PubMedCrossRefGoogle Scholar
  42. 42.
    Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83–91PubMedCrossRefGoogle Scholar
  43. 43.
    Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet 1993; 341: 11–3PubMedCrossRefGoogle Scholar
  44. 44.
    Kanis JA, Johnell O, Gullberg B, et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992; 305: 1124–8PubMedCrossRefGoogle Scholar
  45. 45.
    Silverman SL, Moniz C, Andriano K, et al. Salmon-calcitonin nasal spray prevents vertebral fractures in established osteoporosis: final world wide results of the ‘PROOF’ study [abstract]. Calcif Tissue Int 1999; 64 Suppl. 1: S43Google Scholar
  46. 46.
    Whittington R, Faulds D. Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease. Pharmacoeconomics 1994; 5 (6)Google Scholar
  47. 47.
    Michaëlsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. BMJ 1998; 316: 1858–63PubMedCrossRefGoogle Scholar
  48. 48.
    Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987; 317: 1169–74PubMedCrossRefGoogle Scholar
  49. 49.
    Komulainen MH, Kröger H, Tuppurainen MT, et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women: a 5 year randomized trial. Maturitas 1998; 31: 45–54PubMedCrossRefGoogle Scholar
  50. 50.
    Windeler J, Lange S. Events per person year: a dubious concept. BMJ 1995; 310: 454–6PubMedCrossRefGoogle Scholar
  51. 51.
    Vestergaard P, Hermann AP, Gram J, et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 1997; 28: 137–45PubMedCrossRefGoogle Scholar
  52. 52.
    Weinstein MC. Estrogen use in postmenopausal women: costs, risks, and benefits. N Engl J Med 1980; 303: 308–16PubMedCrossRefGoogle Scholar
  53. 53.
    Cheung AP, Wren BG. A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 1992; 156: 312–6PubMedGoogle Scholar
  54. 54.
    Ryan PJ, Harrison R, Blake GM, et al. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol 1992; 99: 325–8PubMedCrossRefGoogle Scholar
  55. 55.
    Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047–59Google Scholar
  56. 56.
    Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–93PubMedCrossRefGoogle Scholar
  57. 57.
    Beresford SAA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458–61PubMedCrossRefGoogle Scholar
  58. 58.
    Weinstein MC, Tosteson ANA. Cost-effectiveness of hormone replacement. Ann N Y Acad Sci 1990; 592: 162–72PubMedCrossRefGoogle Scholar
  59. 59.
    Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy. I: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979; 5353: 277–81Google Scholar
  60. 60.
    Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–3PubMedCrossRefGoogle Scholar
  61. 61.
    Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–61PubMedCrossRefGoogle Scholar
  62. 62.
    Fitzpatrick LA, Litin SC, Bell MR. The women’s health initiative: a heart-to-HRT conversation [editorial]. Mayo Clin Proc 2000; 75: 559–61PubMedCrossRefGoogle Scholar
  63. 63.
    Hulley S, Grady D, Bush T, et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–13PubMedCrossRefGoogle Scholar
  64. 64.
    Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the heart and estrogen/progestin replacement study. Ann Intern Med 2000; 132: 689–96PubMedGoogle Scholar
  65. 65.
    Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522–9PubMedCrossRefGoogle Scholar
  66. 66.
    Gorsky RD, Koplan JP, Peterson HB, et al. Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis. Obstet Gynecol 1994; 83: 161–6PubMedGoogle Scholar
  67. 67.
    Tang M, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996; 348: 429–32PubMedCrossRefGoogle Scholar
  68. 68.
    Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA 2000; 283: 1007–15PubMedCrossRefGoogle Scholar
  69. 69.
    Seshadri S, Wolf PA, Beiser A, et al. Lifetime risk of dementia and Alzheimer’s disease: the impact of mortality on risk estimates in the Framingham Study. Neurology 1997; 49: 1498–504PubMedCrossRefGoogle Scholar
  70. 70.
    Daly E, Roche M, Barlow D, et al. HRT: an analysis of benefits, risks and costs. Br Med Bull 1992; 48: 368–400PubMedGoogle Scholar
  71. 71.
    Browner WS, Pressman AR, Nevitt MC, et al. Mortality following fractures in older women: the study of osteoporotic fractures. Arch Intern Med 1996; 156: 1521–5PubMedCrossRefGoogle Scholar
  72. 72.
    Nettleman MD, Alsip J, Schrader M, et al. Predictors of mortality after acute hip fracture. J Gen Intern Med 1996; 11: 765–7PubMedCrossRefGoogle Scholar
  73. 73.
    Recker RR, Hinders S, Davies KM, et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 1996; 11: 1961–6PubMedCrossRefGoogle Scholar
  74. 74.
    Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670–6PubMedCrossRefGoogle Scholar
  75. 75.
    Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124: 400–6PubMedGoogle Scholar
  76. 76.
    Kotowicz MA, Melton III LJ, Cooper C, et al. Risk of hip fracture in women with vertebral fracture. J Bone Mineral Res 1994; 9: 599–605CrossRefGoogle Scholar
  77. 77.
    Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12: 1–12Google Scholar
  78. 78.
    Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000; 160: 517–25PubMedCrossRefGoogle Scholar
  79. 79.
    Christensen PM, Kristiansen IS, Brøsen K, et al. Compliance to bisphosphonates: a population-based study using a prescription database [abstract]. Br J Clin Pharmacol 2000; Suppl.: 277Google Scholar
  80. 80.
    Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265–71PubMedCrossRefGoogle Scholar
  81. 81.
    Storm T, Kollerup G, Thamsborg G, et al. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 1996; 23: 1560–4PubMedGoogle Scholar
  82. 82.
    Thomson ABR, Hunt RH, Lanza FL, et al. Risedronate has significantly lower incidence of gastric ulcers compared to alendronate [abstract]. Osteoporos Int 2000; 11 Suppl. 2: S201–2Google Scholar
  83. 83.
    Torgerson D, Donaldson C, Reid D. Using economics to prioritize research: a case study of randomized trials for the prevention of hip fractures due to osteoporosis. J Health Serv Res Policy 1996; 1: 141–6PubMedGoogle Scholar
  84. 84.
    Feskanich D, Willett WC, Stampfer MJ, et al. A prospective study of thiazide use and fractures in women. Osteoporos Int 1997; 7: 79–84PubMedCrossRefGoogle Scholar
  85. 85.
    Adami S. Effects of Evista on fracture incidence in postmenopausal women wih osteoporosis [abstract]. Calcif Tissue Int 2000; 66 Suppl. 1: S128Google Scholar
  86. 86.
    Black DM, Blackwell T, Ettinger B, et al. Does raloxifene reduce non-vertebral fracture risk in women with very low BMD: results from the MORE study [abstract]. Osteoporos Int 2000; 11 Suppl. 2: S89Google Scholar
  87. 87.
    Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. In: The Cochrane Library, Issue 2, 2000. Oxford: Update Software, 2000Google Scholar
  88. 88.
    Myers AH, Young Y, Langlois JA. Prevention of falls in the elderly. Bone 1996; 18: 87S–101SPubMedCrossRefGoogle Scholar
  89. 89.
    Poulstrup A. Project on falls in Vejle County 1985–88 [in Danish]. 1st ed. Jelling: Jelling Bogtrykkeri A/S, 1989Google Scholar
  90. 90.
    Clark AP, Schuttinga JA. Targeted estrogen/progesterone replacement therapy for osteoporosis: calculation of health care cost savings. Osteoporos Int 1992; 2: 195–200PubMedCrossRefGoogle Scholar
  91. 91.
    Torgerson DJ, Kanis JA. Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. QJM 1995; 88 (2): 135–9PubMedGoogle Scholar
  92. 92.
    Kristiansen IS, Falch JA, Andersen L, et al. Use of alendronate in osteoporosis: is it cost-effective? Tidsskr Nor Laegeforen 1997; 117: 2619–22PubMedGoogle Scholar
  93. 93.
    Visentin P, Ciravegna R, Fabris F. Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 1997; 26: 185–92PubMedCrossRefGoogle Scholar
  94. 94.
    Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 1996; 6: 265–75PubMedCrossRefGoogle Scholar
  95. 95.
    Vestergaard P, Mosekilde L. Costs of different intervention strategies to prevent hip fractures. Ugeskr Laeger 1999; 161: 4400–5PubMedGoogle Scholar
  96. 96.
    de Laet CE, van Hout BA, Burger H, et al. Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 1999; 10: 66–72PubMedCrossRefGoogle Scholar
  97. 97.
    Jonsson B, Christiansen C, Johnell O, et al. Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 1995; 5: 136–42PubMedCrossRefGoogle Scholar
  98. 98.
    Brainsky A, Glick H, Lydick E, et al. The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc 1997; 45: 281–7PubMedGoogle Scholar
  99. 99.
    Zethraeus N, Stromberg L, Jonsson B, et al. The cost of a hip fracture: estimates for 1,709 patients in Sweden. Acta Orthop Scand 1997; 68: 13–7PubMedCrossRefGoogle Scholar
  100. 100.
    Farnworth MG, Kenny P, Shiell A. The costs and effects of early discharge in the management of fractured hip [published erratum appears in Age Ageing 1995 Jul; 24 (4): 367]. Age Ageing 1994; 23: 190–4PubMedCrossRefGoogle Scholar
  101. 101.
    Cameron ID, Lyle DM, Quine S. Cost effectiveness of accelerated rehabilitation after proximal femoral fracture. J Clin Epidemiol 1994; 47: 1307–13PubMedCrossRefGoogle Scholar
  102. 102.
    Hollingworth W, Todd C, Parker M, et al. Cost analysis of early discharge after hip fracture. BMJ 1993; 307: 903–6PubMedCrossRefGoogle Scholar
  103. 103.
    Randell A, Sambrook PN, Nguyen TV, et al. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int 1995; 5: 427–32PubMedCrossRefGoogle Scholar
  104. 104.
    Borgquist L, Lindelow G, Thorngren KG. Costs of hip fracture: rehabilitation of 180 patients in primary health care. Acta Orthop Scand 1991; 62: 39–48PubMedCrossRefGoogle Scholar
  105. 105.
    Levy E. Cost analysis of osteoporosis related to untreated menopause. Clin Rheumatol 1989; 8 Suppl. 2: 76–82PubMedCrossRefGoogle Scholar
  106. 106.
    Lane A. Direct costs of osteoporosis for New Zealand women. Pharmacoeconomics 1996; 9 (3): 231–45PubMedCrossRefGoogle Scholar
  107. 107.
    Stromberg L, Ohlen G, Svensson O. Prospective payment systems and hip fracture treatment costs. Acta Orthop Scand 1997; 68: 6–12PubMedCrossRefGoogle Scholar
  108. 108.
    Schurch MA, Rizzoli R, Mermillod B, et al. A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 1996; 11: 1935–42PubMedCrossRefGoogle Scholar
  109. 109.
    Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997; 103: 20S–5SPubMedCrossRefGoogle Scholar
  110. 110.
    Finsen V, Borset M, Rossvoll I. Mobility, survival and nursing home requirements after hip fracture. Ann Chir Gynaecol 1995; 84: 291–4PubMedGoogle Scholar
  111. 111.
    Zethraeus N, Gerdtham UG. Estimating the costs of hip fracture and potential savings. Int J Technol Assess Health Care 1998; 14: 255–67PubMedCrossRefGoogle Scholar
  112. 112.
    French FH, Torgerson DJ, Porter RW. Cost analysis of fracture of the neck of femur. Age Ageing 1995; 24: 185–9PubMedCrossRefGoogle Scholar
  113. 113.
    Parker MJ, Myles JW, Anand JK, et al. Cost-benefit analysis of hip fracture treatment. J Bone Joint Surg Br 1992; 74: 261–4PubMedGoogle Scholar
  114. 114.
    Schroder HM. The cost of hospitalizing hip fracture patients has increased despite shorter hospitalization time. Injury 1991; 22: 135–8PubMedCrossRefGoogle Scholar
  115. 115.
    Thorngren KG. Cost comparison in hip fracture treatment. Acta Orthop Scand 1991; 241 Suppl.: 38–9Google Scholar
  116. 116.
    Torgerson DJ, Reid DM. The economics of osteoporosis and its prevention: a review. Pharmacoeconomics 1997; 11 (2): 126–38PubMedCrossRefGoogle Scholar
  117. 117.
    Knogleskørhed (Konsensus-rapport 9.–11. januar 1995). 1st ed. Copenhagen: Statens Sundhedsvidenskabelige Forskningsråd og Dansk Sygehus Institut, 1995Google Scholar
  118. 118.
    Geelhoed E, Harris A, Prince R. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health 1994; 18: 153–60PubMedCrossRefGoogle Scholar
  119. 119.
    Cranney A, Welch V, Adachi JD, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis [CD-ROM and online]. Cochrane Database Syst Rev 2000; (2): CD001983Google Scholar
  120. 120.
    Roux C, Oriente P, Laan R, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 1998; 83: 1128–33PubMedCrossRefGoogle Scholar
  121. 121.
    Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis [CD-ROM and online]. Cochrane Database Syst Rev 2000; (2): CD001347Google Scholar
  122. 122.
    Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis [CD-ROM and online]. Cochrane Database Syst Rev 2000; (2): CD000952Google Scholar
  123. 123.
    Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;: 382–7Google Scholar
  124. 124.
    Rosner AJ, Grima DT, Torrance GW, et al. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998; 14 (5): 559–73PubMedCrossRefGoogle Scholar
  125. 125.
    Mortensen L, Charles P, Bekker PJ, et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83: 396–402PubMedCrossRefGoogle Scholar
  126. 126.
    Phillips CJ, Moore RA. Developing a strategy for the prevention of hip fractures in the elderly due to osteoporosis: the application of economics to the findings from a clinical trial. Int J Clin Pract 1998; 52: 335–40PubMedGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Peter Vestergaard
    • 1
    • 3
  • Lars Rejnmark
    • 1
    • 2
  • Leif Mosekilde
    • 1
  1. 1.Department of Endocrinology and Metabolism, Aarhus AmtssygehusAarhus University HospitalAarhusDenmark
  2. 2.Institute of Clinical PharmacologyAarhus UniversityAarhusDenmark
  3. 3.The Osteoporosis ClinicAarhus AmtssygehusAarhus CDenmark

Personalised recommendations